{
  "docId": "019de070-301c-70bd-a010-9a413c6f1b9e",
  "docSlug": "98da217852cb2fba9da82ffbc6cfdefe",
  "documentTitle": "Genetron | IPO Presentation Deck | 41 slides",
  "authorId": "genetron",
  "authorName": "Genetron",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 20,
  "pageCount": 41,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The map visualizes the geographic footprint of regulatory/procurement approvals for Genetron's assays.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-301c-70bd-a010-9a413c6f1b9e/20",
  "deckHref": "/decks/019de070-301c-70bd-a010-9a413c6f1b9e",
  "deckJsonHref": "/decks/019de070-301c-70bd-a010-9a413c6f1b9e.json",
  "deckAnchorHref": "/decks/019de070-301c-70bd-a010-9a413c6f1b9e#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "Note: As of May 26, 2020 (1) Lung 8 IVD assay is pending approval in Anhui, Zhejiang and Sichuan",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d020869b-70e2-473d-b944-6ca1fd7ae81b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.55,
        "y": 0.18
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "map",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17224542-b2cc-4275-a65d-6a51fcdb0b92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.55,
        "y": 0.66
      },
      "kind": "legend",
      "text": "Provinces with Genetron's assays approved / pending approval for sunshine medical centralized procurement and / or LDT services included in the charge master list",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67626b7f-b738-486d-8f83-1e2744108fbb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.07,
        "y": 0.35
      },
      "kind": "list",
      "text": "IVD Sunshine centralized procurement: TERT and IDH1 IVD assays: approved in 10 provinces and 3 provinces pending approval; Lung 8 IVD assay was approved in Shandong and 3 provinces pending approval(1)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf56ab77-b663-465d-8a40-e242f6f1d443",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.07,
        "y": 0.58
      },
      "kind": "list",
      "text": "LDT services have been included in the charge master in 2 provinces, which is a significant step towards having LTD services covered by the basic medical insurance",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7c98ef9-304d-4c3a-85bf-a9f1ccc75154",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.07,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Cancer molecular profiling is expected to be covered by public medical insurance in the near future",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1adb1d17-6f01-4f40-9641-9bd2072334fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Significant progress made on public medical insurance",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a67fa3f-a4e8-41a8-9ee4-4219ca5b5654",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 23,
      "from": 20,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "61b77ce9-0007-412c-946f-5eeb0ac73f80",
      "evidence": "Slides 20-23 discuss the significant cost advantage presented by Genetron's proprietary technologies and recent development",
      "position": 0,
      "objective": "Highlight the benefits of Genetron's proprietary technologies and significant progress on public medical insurance",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}